Brokerages Set AstraZeneca PLC (LON:AZN) PT at GBX 7,542.80

Shares of AstraZeneca PLC (LON:AZN) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is GBX 7,542.80 ($97.40).

AZN has been the subject of a number of analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Berenberg Bank reissued a “buy” rating and set a GBX 140 ($1.81) price target on shares of AstraZeneca in a research report on Monday, January 27th. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Friday, March 7th.

AstraZeneca Price Performance

Shares of LON AZN opened at £116.08 ($149.90) on Friday. AstraZeneca has a fifty-two week low of GBX 9,670 ($124.87) and a fifty-two week high of £133.88 ($172.88). The company has a 50 day simple moving average of £115.32 and a two-hundred day simple moving average of £113.21. The company has a market capitalization of £223.34 billion, a price-to-earnings ratio of 31.82, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.